비소세포성 환자에서 Anaplastic Lymphoma Kinase 유전자 변이 진단검사
Diagnostic Tests for Anaplastic Lymphoma Kinase Gene Rearrangement in Non-Small-Cell Lung Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Accurate determination of anaplastic lymphoma kinase (ALK) rearrangement is important in lung cancer patients, especially in determining their eligibility for crizotinib therapy. Basically immunohistochemistry (IHC) mothod and fluorescence in situ hybridization (FISH) has been used to detect ALK gene rearrangement. IHC mothod has been used for primary test and FISH has been regarded as the gold standard method for detecting ALK rearrangement in determining their eligibility for crizotinib therapy. However FISH requires a fluorescence microscope, and the signals are labile and rapidly fade over time. In this study, we reviewed current diagnostic tests for ALK gene rearrangement in non-small-cell lung cancer in Korea and potentiality of the new improved test for new alternative test to FISH
Abstract
Accurate determination of anaplastic lymphoma kinase (ALK) rearrangement is important in lung cancer patients, especially in determining their eligibility for crizotinib therapy. Basically immunohistochemistry (IHC) mothod and fluorescence in situ hybridization (FISH) has been used to detect ALK gene rearrangement. IHC mothod has been used for primary test and FISH has been regarded as the gold standard method for detecting ALK rearrangement in determining their eligibility for crizotinib therapy. However FISH requires a fluorescence microscope, and the signals are labile and rapidly fade over time. In this study, we reviewed current diagnostic tests for ALK gene rearrangement in non-small-cell lung cancer in Korea and potentiality of the new improved test for new alternative test to FISH
참고문헌 (9)
- "National Cancer Information Center"[URL]
- 박동윤, "폐암을 대상으로 한 transcriptome 및 methylome 연구에 대하여", 생화학분자생물학뉴스, 2008(9), pp.1~5
- Peng L, "Methodological Limitations in Determining Astrocytic Gene Expression", Front Endocrinol (Lausanne), 4, pp.176~ (2013)
- Gridelli C, "ALK inhibitors in the treatment of advanced NSCLC", Cancer Treat Rev, 40, pp.300~306 (2014)
- Soda M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", Nature, 448, pp.561~566 (2007)
- Toyokawa G, "Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation", J Thorac Oncol, 8, pp.e96~e98 (2013)
- Takeuchi K, "RET, ROS1 and ALK fusions in lung cancer", Nat Med, 18, pp.378~381 (2012)
- Gautschi O, "Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer", Onkologie, 36, pp.342~347 (2013)
- Han XH, "Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer", Virchows Arch, 463, pp.583~591 (2013)